Forbedring av mobilitet etter revaskularisering ved perifer arteriesykdom (IMPACT PAD)
Forbedring av mobilitet etter revaskularisering ved perifer arteriesykdom: IMPACT PAD-forsøket
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.
In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.
Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Mary M McDermott, MD
- Telefonnummer: 312-503-6438
- E-post: mdm608@northwestern.edu
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85724
- Rekruttering
- University of Arizona
-
Ta kontakt med:
- Wei Zhou, MD
-
-
California
-
Downey, California, Forente stater, 90242
- Rekruttering
- Rancho Research Institute
-
Ta kontakt med:
- Tze-Woei Tan, MD
-
-
Florida
-
Tampa, Florida, Forente stater, 33606
- Rekruttering
- University of South Florida
-
Ta kontakt med:
- Ulka Sachdev, MD
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30307
- Rekruttering
- Emory University School of Medicine
-
Ta kontakt med:
- Olamide Alabi, MD
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Ta kontakt med:
- Tamar Polonsky, MD
- Telefonnummer: 773-702-6153
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University Feinberg School of Medicine
-
Hovedetterforsker:
- Mary M McDermott, MD
-
Ta kontakt med:
- Kathryn Domanchuk, BS
- Telefonnummer: 312-503-6438
- E-post: k-domanchuk@northwestern.edu
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Henry Ford Health
-
Ta kontakt med:
- Jonathan Ehrman, PhD
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03766
- Rekruttering
- Dartmouth Hitchcock Medical Center
-
Ta kontakt med:
- Philip P Goodney, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.
Exclusion Criteria:
- History of leg amputation, not including toe and partial foot amputation
- Active gangrene
- Active limb threatening ischemia
- Already exercising at a level consistent with exercise intervention, using investigator discretion.
- Unstable angina
- Unwilling to drink study beverages
- Unwilling to adhere to the interventions and complete follow-up testing
- Currently taking sildenafil, tadalafil, or related drugs.
- Unwilling to accept randomization into either group (home-based exercise or attention control)
- Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
- History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
- Baseline blood pressure <100/45.
- Wheelchair confinement or requiring a walker to ambulate
- Walking is limited by a condition other than PAD
- Current foot ulcer
- Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
- Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
- Allergy to beetroot juice
- Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
- Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
- Visual impairment that limits walking ability.
- Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
- Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
- Planning to begin a supervised treadmill exercise program in the next 12 months.
- Heart attack or stroke in previous three months prior to baseline testing.
- An eGFR value <30 or potassium >5.0.
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Home based exercise + nitrate rich beetroot juice
This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. |
|
Placebo komparator: Home-based exercise + placebo
This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. |
|
Eksperimentell: Attention control + nitrate-rich beetroot juice
This group will be participating in attention control and drinking nitrate rich beetroot juice for six months. |
Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
|
Placebo komparator: Attention control + placebo
This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months. |
Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Six-Minute Walk Distance 6-month change
Tidsramme: Baseline to 6-month follow-up
|
Distance walked in six minutes |
Baseline to 6-month follow-up
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Tidsramme: Baseline to 6-month follow-up.
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 6-month follow-up.
|
|
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Tidsramme: Baseline to 12-month follow-up
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 12-month follow-up
|
|
PROMIS Mobility Questionnaire Score 6-month change
Tidsramme: Baseline to 6-month follow-up
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 6-month follow-up
|
|
PROMIS Mobility Questionnaire Score 12-month change
Tidsramme: Baseline to 12-month follow-up.
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 12-month follow-up.
|
|
Prevention of Hemodynamic Failure of The Revascularized Vessel
Tidsramme: Baseline to 12 month follow-up
|
Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel. |
Baseline to 12 month follow-up
|
|
Change in 6-minute walk distance
Tidsramme: 12 month follow-up
|
Change in 6-minute walk distance between baseline and 12-month follow-up |
12 month follow-up
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Six-Minute Walk Distance
Tidsramme: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
Change in six-minute walk distance 24 hours after the final study beverage |
Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
|
Plasma Nitrite Levels
Tidsramme: Baseline to 6-month follow-up
|
Change in plasma nitrite levels in the blood at 6-month follow-up |
Baseline to 6-month follow-up
|
|
BH4/BH2 6-month change
Tidsramme: Baseline to 6-month follow-up
|
Change in BH4/BH2 ratio |
Baseline to 6-month follow-up
|
|
Progression of PAD
Tidsramme: Baseline to 12-month follow-up
|
Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up. |
Baseline to 12-month follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Aterosklerose
- Arteriosklerose
- Arterielle okklusive sykdommer
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Perifer arteriell sykdom
- Mobilitetsbegrensning
- Perifere vaskulære sykdommer
- Intermitterende Claudication
- Organiske kjemikalier
- Uorganiske kjemikalier
- Nitrogenforbindelser
- Anioner
- Ioner
- Elektrolytter
- Salpetersyre
- Nitrater
Andre studie-ID-numre
Andre studie-ID-numre
- STU00222333
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-delingstidsramme
Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.
Tilgangskriterier for IPD-deling
Per BioLINCC
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .